Melbourne, Australia and Oxford, UK – 3 August 2026, Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy. The FDA’s Fast Track program facilitates the […]

Melbourne, Australia and Oxford, UK– 23 June 2025, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site. Adrian is hugely experienced in the field with more than 20 years of […]

Melbourne, Australia and Oxford, UK– 21 January 2025, Aravax, a clinical-stage biotechnology company developing precisely targeted next-generation immunotherapies for the treatment of food allergy, today announces the appointment of Aled Williams as Chief Business Officer as the company continues its development into an international leader in food allergies. Aled’s appointment follows the establishment of the […]

Melbourne, Australia – 28 October 2024: Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces it has completed patient recruitment into its Phase 2 study (AVX-201) of its novel, precision therapy PVX108 for the treatment of peanut allergy. Aravax’s PVX108 is an advanced immunotherapy designed to […]

23 Jan 2024: Aravax, a clinical stage biotechnology company developing the first rationally designed and precisely targeted immunotherapeutic for peanut allergy (PVX108), today announces it has closed its Series B funding round with a total of US$42.2m. In December 2022, Aravax announced the opening of the Series B with US$20m from Brandon Capital and Tenmile. […]